• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pacira Pharm Inc (NQ: PCRX )

    17.24 -0.46 (-2.60%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pacira Pharm Inc

    < Previous 1 2 3 4 5 6 Next >
    Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
    From Pacira BioSciences
    Via GlobeNewswire
    Analyst Ratings For Pacira BioSciences
    Via Benzinga
    PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024
    PCRX stock results show that Pacira BioSciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
    Via Benzinga
    Navigating 4 Analyst Ratings For Pacira BioSciences
    Via Benzinga
    Earnings Scheduled For February 29, 2024
    Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
    Via Benzinga
    Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
    From Pacira BioSciences
    Via GlobeNewswire
    Preview: Pacira BioSciences's Earnings
    Via Benzinga
    NASDAQ:PCRX is an undervalued gem with solid fundamentals.
    PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals. 
    Via Chartmill
    A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
    Via Benzinga
    Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
    From Pacira BioSciences
    Via GlobeNewswire
    Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
    PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals. 
    Via Chartmill
    Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
    Via AB Newswire
    Topics Death
    Exposures Death
    Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
    From Pacira BioSciences
    Via GlobeNewswire
    When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it's a hidden gem with strong fundamentals and an attractive price tag. 
    Via Chartmill
    Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira to Report 2023 Financial Results on Thursday February 29, 2024
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
    From Pacira BioSciences
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals. 
    Via Chartmill
    Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira Appoints Frank D. Lee as Chief Executive Officer
    From Pacira BioSciences
    Via GlobeNewswire
    NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. 
    Via Chartmill
    Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents.
    Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
    Via Chartmill
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.